Molecular determinants of high-affinity drug binding to HERG channels

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 5, 2003, Pages 667-674

  Mitcheson, John S ^a   Perry, Matthew D ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cardiac arrhythmias; Drug induced QT interval prolongation; HERG; High affinity drug binding; Structural basis of drug binding; Voltage gated K + channel

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ANTIARRHYTHMIC AGENT; CHLOROQUINE; CISAPRIDE; CLOFILIUM; DOFETILIDE; HERG CHANNEL BLOCKING AGENT; IBUTILIDE; METHANESULFONANILIDE DERIVATIVE; PIPERANOMETOZINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PROPAFENONE; QUINIDINE; SOTALOL; TERFENADINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHANNEL GATING; DRUG BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; ELECTRIC POTENTIAL; ELECTROCARDIOGRAM; GENE; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN ETHER A GO GO RELATED GENE; NONHUMAN; POTASSIUM CURRENT; PROTEIN STRUCTURE; QT INTERVAL; SIDE EFFECT;

AMINO ACID SEQUENCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BINDING SITES; CATION TRANSPORT PROTEINS; ETHER-A-GO-GO POTASSIUM CHANNELS; LONG QT SYNDROME; MOLECULAR SEQUENCE DATA; PHARMACEUTICAL PREPARATIONS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT;

EID: 0142091429     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. + channels in brain. J Neurosci (2001) 21(13):4609-4624.
2. Kr channels. J Biol Chem (2000) 275(8):5997-6006.
3. + channels and their role in cardiac arrhythmias. Am J Med (2001) 110(1):50-59.
4. Kr: The HERG channel. J Mol Cell Cardiol (2001) 33(5):835-849.
5. Mitcheson JS, Sanguinetti MC: Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels. Cell Physiol Biochem (1999) 9(4-5):201-216.
6. + channels: Friend and foe. Trends Pharmacol Sci (2001) 22(5):240-246.
7. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell (2001) 104(4):569-580. A comprehensive review of the inherited and drug-induced mechanisms of cardiac arrhythmias.
8. Hancox JC, Patel KC, Jones JV: Antiarrhythmics - from cell to clinic: Past, present, and future. Heart (2000) 84(1):14-24.
9. Fermini B, Fossa AA: The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Disc (2003) 2(6):439-447.
10. Redfem WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ et al: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 58(1):32-45.
11. Roy M, Dumaine R, Brown AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation (1996) 94(4):817-823.
12. Kr in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation (1995) 91(6):1799-1806.
13. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA (2000) 97(22):12329-12333. A scanning Ala mutagenesis study that identified the amino acid residues required for high-affinity drug block.
14. 656 is identified as a molecular determinant of dofetilide and quinidine binding.
15. Chen J, Seebohm G, Sanguinetti MC: Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and EAG potassium channels. Proc Natl Acad Sci USA (2002) 99(19):12461-12466. The results of this study suggest that it is the position of inner cavity aromatic residues, rather than inactivation per se, that is critical for high-affinity binding of cisapride.
16. 652 in voltage-dependent block by chloroquine is identified.
17. 656.
18. + channel.
19. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R: Crystal structure and mechanism of a calcium-gated potassium channel. Nature (2002) 417(6888):515-522.
20. + channels.
21. + channel. Nature (2003) 423(6935):42-48. The position of voltage sensor paddles of KvAP channels are determined in open and closed conformations.
22. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R: The open pore conformation of potassium channels. Nature (2002) 417(6888):523-526.
23. Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, Mackinnon R: Crystal structure and functional analysis of the HERG potassium channel N terminus: A eukaryotic PAS domain. Cell (1998) 95(5):649-655.
24. Wang J, Trudeau MC, Zappia AM, Robertson GA: Regulation of deactivation by an amino terminal domain in human ether-a-go-go-related gene potassium channels. J Gen Physiol(1998) 112(5):637-647.
25. + channels. J Gen Physiol (2000) 115(6):749-758.
26. Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC: Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem (1999) 274(15):10113-10118.
27. Kr channel. J Gen Physiol (1996) 107(5):611-619.
28. Schonherr R, Heinemann SH: Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J Physiol London (1996) 493(Pt 3):635-642.
29. Jenke M, Sanchez A, Monje F, Stuhmer W, Weseloh RM, Pardo LA: C-terminal domains implicated in the functional surface expression of potassium channels. EMBO J (2003) 22(3):395-403.
30. + channels. J Biol Chem (2002) 277(21):18994-19000.
31. + channel. Neuron (2001) 32(4):649-656.
32. Snyders DJ, Chaudhary A: High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol (1996) 49(6):949-955.
33. + channel. Open-channel block by methanesulfonanilides. Circ Res (1996) 78(3):499-503.
34. Yellen G: The moving parts of voltage-gated ion channels. Q Rev Biophys (1998) 31(3):239-295. A comprehensive review of the structural basis and molecular motions of voltage-dependent gating processes in ion channels.
35. Smith PL, Baukrowitz T, Yellen G: The inward rectification mechanism of the HERG cardiac potassium channel. Nature (1996) 379(6568):833-836.
36. + channels. Circ Res (1998) 82(3):386-395.
37. Liu J, Zhang M, Jiang M, Tseng GN: Structural and functional role of the extracellular S5-P linker in the HERG potassium channel. J Gen Physiol (2002) 120(5):723-737.
38. Mitcheson JS, Hancox JC: An investigation of the role played by the E-4031-sensitive (rapid delayed rectifier) potassium current in isolated rabbit atrioventricular nodal and ventricular myocytes. Pflug Arch Eur J Physiol (1999) 438(6):843-850.
39. Hancox JC, Levi AJ, Witchel HJ: Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential. Pflug Arch Eur J Physiol (1998) 436(6):843-853.
40. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J (1998) 74(1):230-241.
41. + channels. J Physiol London (2001) 537(Pt 3):843-851.
42. + channels expressed in Xenopus oocytes. Am J Physiol (1997) 272(3 Pt 2):H1309-H1314.
43. Kiehn J, Lacerda AE, Wible B, Brown AM: Molecular physiology and pharmacology of HERG - Single-channel currents and block by dofetilide. Circulation (1996) 94(10):2572-2579.
44. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther (1992) 262(2):809-817.
45. Kr channels by closure of the activation gate upon repolarization.
46. Mitcheson JS, Chen J, Sanguinetti MC: Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol (2000) 115(3):229-240. This study confirmed the drug-trapping hypothesis for slow recovery of HERG channels from block by methanesulfonanilides, and provides evidence for the location of the drug-binding site within the inner cavity of the channel.
47. + channels. This implies that, in these channels, the pore structure is different from that of the KcsA crystal.
48. + channels by vesnarinone. Mol Pharmacol (2001) 60(2):244-253.
49. Dougherty DA: Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp. Science (1996) 271(5246):163-168.
50. Witchel HJ, Milnes JT, Mitcheson JS, Hancox JC: Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K channels expressed in mammalian cell lines and Xenopus ooctyes. J Pharmacol Toxicol Methods (2003): in press.
51. Warmke JW, Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA (1994) 91(8):3438-3442.
52. Herzberg IM, Trudeau MC, Robertson GA: Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-EAG channels. J Physiol London (1998)511(Pt 1):3-14.
53. + channels. Mol Pharmacol (2001) 60(6):1343-1348. This study provides further evidence that the lack of inactivation of EAG channels is the cause of the relative insensitivity of this channel to HERG channel blockers, despite having the same key inner cavity residues as HERG.
54. o and C-type inactivation. FEBS Lett (1997) 417(1):43-47.
55. Volberg WA, Koci BJ, Su W, Lin J, Zhou J: Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther (2002) 302(1):320-327.
56. + channels Isolated from Centruroides noxius scorpion venom. FASEB J (1999) 13(8):953-962.
57. Korolkova YV, Kozlov SA, Lipkin AV, Pluzhnikov KA, Hadley JK, Filippov AK, Brown DA, Angelo K, Strobaek D, Jespersen T, Olesen SP et al: An ERG channel inhibitor from the scorpion Buthus eupeus. J Biol Chem (2001) 276(13):9868-9876.
58. Pardo-Lopez L, Garcia-Valdes J, Gurrola GB, Robertson GA, Possani LD: Mapping the receptor site for ergtoxin, a specific blocker of ERG channels. FEBS Lett (2002) 510(1-2):45-49.
59. Pardo-Lopez L, Zhang M, Liu J, Jiang M, Possani LD, Tseng GN: Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule. J Biol Chem (2002) 277(19):16403-16411.
60. Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, Tseng GN: BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J (2003) 84(5):3022-3036.
61. Torres AM, Bansal P, Alewood PF, Bursill JA, Kuchel PW, Vandenberg JI: Solution structure of CnErg1 (Ergtoxin), a HERG specific scorpion toxin. FEBS Lett (2003) 539(1-3):138-142.
62. Peadstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D: Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett (2003) 13(10):1829-1835.
63. + channel blockers. J Med Chem (2002) 45(18):3844-3853.